ReviewJournal of neural transmission (Vienna, Austria : 1996)2026
Alcohol withdrawal and the sigma receptor: exploring the link between withdrawal and cognitive impairment.
Review in Journal of neural transmission (Vienna, Austria : 1996), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alcohol withdrawal syndrome is increasingly recognized as a significant public health concern in India and worldwide, highlighting the pressing need for innovative therapeutic strategies. The Sigma-1 receptor system has recently garnered attention as a potential target in the treatment of Alcohol withdrawal syndrome. Evidence from preclinical animal studies indicates that Sigma-1 receptor antagonists can effectively reduce alcohol intake, diminish the motivation to drink, and inhibit alcohol-seeking behaviors. They also show potential in addressing cognitive deficits, motor function disruptions, and relapse-like behaviors. These findings suggest a pivotal role of Sigma-1 receptor in modulating addiction-related mechanisms. Although current FDA-approved treatments such as disulfiram, naltrexone, and acamprosate offer some clinical benefits, the underlying pathways through which Sigma-1 receptor influences alcohol dependence are not yet fully elucidated. Continued research into Sigma-1 receptor -mediated mechanisms may not only enhance our neurobiological understanding of Alcohol Used Disorder and Alcohol Withdrawal Syndrome but also support the development of more precise and effective treatment options.
Indexed as
Identifiers
41094122What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.